Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
about
Novel approaches to inhibit HIV entryClinical significance of HIV-1 coreceptor usage.Bioinformatic analysis of HIV-1 entry and pathogenesis.Access denied? The status of co-receptor inhibition to counter HIV entryCharacterization of partial and near full-length genomes of HIV-1 strains sampled from recently infected individuals in São Paulo, BrazilHIV-1 drug resistance and resistance testing.HIV-1 tropism dynamics and phylogenetic analysis from longitudinal ultra-deep sequencing data of CCR5- and CXCR4-using variants.Frequent detection of CXCR4-using viruses among Brazilian blood donors with HIV-1 long-standing infection and unknown clinical stage: Analysis of massive parallel sequencing dataX4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process.HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samplesEnvelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individualsHIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Tropism testing in the clinical management of HIV-1 infection.Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infectionHIV-1 antiretroviral resistance: scientific principles and clinical applicationsCo-receptor usage and prediction of V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province.Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay.HIV-1 tropism and liver fibrosis in HIV-HCV co-infected patientsImproved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.A diagnostic HIV-1 tropism system based on sequence relatedness.Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment optionsCharacterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies.Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy.Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa.Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switchingPrevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana.Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or DeathPredicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic.Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes.HIV-1 pathogenesis: the virus.Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression.The HIV-1 env protein: a coat of many colors.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTA stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects.Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda
P2860
Q27013957-59B1E78E-F7D5-4259-A3E6-151BC7B75A3FQ27691426-F0F3CC1A-A231-4968-BEEC-6AE465D3B22FQ27693321-8DE41505-9239-41FB-BE73-7CF3AAFEA4E1Q28300187-C35E5F3D-DAA5-4425-90C3-F89D04146C8AQ28477491-82D46DD8-E774-418E-8573-FB6ECECB5B1EQ30245693-DC89A16B-EA04-4CEB-A2DD-86F17165ED71Q30836893-FAC7AD85-F593-4D96-A415-92133C898288Q31044033-2FA6BF21-120B-4A34-9384-30CB9E0A991EQ31117473-6F43D524-8A38-4431-9F69-826895C88DBEQ33521125-2E92AAB2-DC80-45EC-8948-666EDD3A5011Q33636669-A809E555-08C2-4234-BD54-C99A97082FD0Q33685141-629DD6EF-891F-4526-8647-8A3790087664Q33807529-CC44C71A-58A7-492E-AA27-C267E135FF8AQ33869686-8ED43466-4A64-47FB-920D-071F977C3544Q34190296-9A64D75C-1ACA-480C-8C94-5A73B2A0AC6FQ34280466-D1FEF789-9908-44A2-8F27-590125D82CD1Q34332104-2ABBE3F2-1FEB-4B67-BA66-2ED81D59F9A6Q34489614-1902B9DA-87F2-4048-ADEB-A72152940DCDQ34505231-71521A3A-4D13-47D7-A331-BD0EEE64FFB0Q34623149-78409258-CD5F-40E5-8B7B-C8DB063CD6D0Q34983107-3998EF87-61F7-46D1-85A8-333C12A6CAEFQ35274968-B25D08C6-C08F-40E1-895B-63B420F61D7FQ35386184-E8EAE600-0D81-4E5C-8813-FB3C357631B6Q35441620-21A0DB10-C90A-4C68-9AD4-A0D9095D1EF4Q35784605-0A67A995-E893-4D4A-BF63-3D8CCB14B7ABQ35838609-7C9F3DEF-0C5E-434D-A0CF-24D47BF29A95Q35862329-CD2A6A88-A23B-4285-A178-1F33335FBE76Q35947621-A668C534-7A18-49FA-87ED-C8FA36561AA2Q35964202-EBEA106C-384B-43CD-A726-EA7C67523E36Q36191170-E8881026-E4D8-4741-BD2E-BE0180410B1AQ36262454-5C0AADA7-90FC-444E-80F4-5085B96D0CB0Q36480496-642B2AD7-8B63-452A-9261-39D6206AE074Q36497842-92A6A69B-9391-4976-93F6-F1F28678B245Q36526530-B8D944C1-8E6F-43E2-A4AC-5AD26F59C84BQ36558240-53BF89B4-63CB-498F-8517-4AA398475FECQ36846285-1CA904A6-F856-4A2F-98FA-44847DCEB1A9Q36856091-8BEF2CD9-D6B2-426B-AB75-0F40A33CD0D4Q36900010-471BD5E1-F847-4990-83A5-34A9D1019DDBQ37042552-1FEDCB58-3552-462B-BAD3-A617C4699B60Q37048027-39C5FCD4-ABC9-438B-BB85-DFD69404151E
P2860
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Prevalence of CXCR4 tropism am ...... ients with detectable viremia.
@en
Prevalence of CXCR4 tropism am ...... ients with detectable viremia.
@nl
type
label
Prevalence of CXCR4 tropism am ...... ients with detectable viremia.
@en
Prevalence of CXCR4 tropism am ...... ients with detectable viremia.
@nl
prefLabel
Prevalence of CXCR4 tropism am ...... ients with detectable viremia.
@en
Prevalence of CXCR4 tropism am ...... ients with detectable viremia.
@nl
P2093
P356
P1476
Prevalence of CXCR4 tropism am ...... ients with detectable viremia.
@en
P2093
David W Williamson
Harry Lampiris
Jeffrey N Martin
Joseph M McCune
Michael Bates
P Richard Harrigan
Peter W Hunt
Rebecca Hoh
Richard W Price
Serena S Spudich
P304
P356
10.1086/507312
P407
P577
2006-08-29T00:00:00Z